The MicroRNA-23b/27b/24 Cluster Promotes Breast Cancer Lung Metastasis by Targeting Metastasis-suppressive Gene Prosaposin

MicroRNAs (miRNAs) have been shown to function as key regulators of tumor progression and metastasis. Recent studies have indicated that the miRNAs comprising the miR-23b/27b/24 cluster might influence tumor metastasis, although the precise nature of this regulation remains unclear. Here, expression of the miR-23b/27b/24 cluster is found to correlate with metastatic potential in mouse and human breast cancer cell lines and is elevated in metastatic lung lesions in human breast cancer patients. Ectopic expression of the miRNAs in the weakly metastatic mouse 4T07 mammary tumor cell line had no effect on proliferation or morphology of tumor cells in vitro but was found to increase lung metastasis in a mouse model of breast cancer metastasis. Furthermore, gene expression profiling analysis of miRNA overexpressing 4T07 cells revealed the direct targeting of prosaposin (PSAP), which encodes a secreted protein found to be inversely correlated with metastatic progression in human breast cancer patients. Importantly, ectopic expression of PSAP was able to suppress the metastatic phenotype in highly metastatic 4T1 and MDA-MB-231 SCP28 cells, as well as in cells ectopically expressing miR-23b/27b/24. These findings support a metastasis-promoting function of the miR-23b/27b/24 cluster of miRNAs, which functions in part through the direct inhibition of PSAP.

MicroRNAs (miRNAs) have been recognized as regulatory RNAs with significant roles in multiple pathological processes. Individual miRNAs have been shown to regulate hundreds of downstream genes, and studies have implicated improper miRNA expression as a causal factor in tumorigenesis and metastasis (1–3). Alterations in miRNA levels are a frequent occurrence in cancer, and miRNA expression patterns can be utilized to stratify cancer subtypes, even in poorly differentiated tumors of ambiguous origins (4, 5). In addition, miRNAs have been identified as significant prognostic and predictive markers during tumor progression. For example, miR-10b (6) and the miR-200 family of miRNAs (7) are correlated with breast cancer metastasis, whereas miR-15b is associated with recurrence in melanoma (8).

Multiple methods have been utilized to examine miRNA expression changes during tumor progression, including sequencing, microarrays, and qRT-PCR approaches (9). Array-based miRNA expression profiling has uncovered broad miRNA changes in cancer cell lines, which can be correlated with metastatic capacity. Tavazoie et al. (10) examined the MDA-MB-231 human breast cancer cell line, along with sublines possessing differing metastatic potential to lung or bone, revealing miR-126 and miR-335 as suppressors of metastasis. In addition, a screen of 51 human breast cancer cell lines revealed tight clustering of miRNA expression changes that corresponded with the breast cancer subtype (11). Importantly, miRNAs have also been associated with causal roles during metastasis, both as mediators (miR-21, miR-373, miR-520c, miR-17–92, miR-10b, miR-9, miR-200) and inhibitors (miR-24, miR-34, miR-15–16) of metastatic progression (3). Many of these miRNAs play functional roles in various defined hallmarksof cancer, including migration and invasion (miR-10b, miR-373, miR-520c, miR-200, miR-34), proliferation and cell death (miR-17–92, miR-21, miR-24), angiogenesis (miR-17–92, miR-210), and colonization (miR-200) (6, 7, 12–14).

Previous studies have implicated the miR-23/27/24 miRNAs in the regulation of tumor progression. These miRNAs are expressed in two separately regulated clusters, comprising 23a/27a/24–2 and miR-23b/27b/24 (15). Expression of the miR-23/27/24 clusters has been linked to bone morphogenetic protein and TGFβ signaling, although the exact regulatory mechanism of each cluster remains unclear (16–18). Sun et al. (16) found that the miRNAs within the miR-23b/27b/24 cluster were independently regulated upon treatment with bone morphogenetic protein inhibitors.
protein-2, with miR-23b decreasing in expression, miR-27b showing no significant changes, and miR-24 levels increasing. In addition, there are conflicting reports regarding the functional role of the miR-23/27/24 clusters during tumor development and metastatic progression. miR-23b has been shown to decrease migration and invasion in vitro (19) and to decrease colon cancer lung metastasis (20) and breast cancer lymph node metastasis in vivo (21). Conversely, ectopic expression of the entire miR-23a/27a/24 cluster increased migration and invasion in breast cancer cells and promoted hepatic metastasis (22). Similarly, miR-24 has been shown to inhibit apoptosis and promote the formation of micrometastases within the lungs of subcutaneously injected mice (23). Finally, although miR-27b has been shown to decrease primary colorectal cancer tumor growth and inhibit angiogenesis (24), miR-27a has been shown to positively correlate with breast cancer progression (25). Thus, the miR-23ab/27ab/24 miRNAs have been shown to possess dichotomous roles during tumor progression. Although it is possible that these contradictory findings are a result of the different model systems employed in the previous reports, further research is required to identify the precise role of the miRNAs during breast cancer invasion and tumor progression.

In this study, we examined the expression of the miR-23/27/24 clusters across multiple isogenic cell line series containing sublines with diverse metastatic propensities. Expression of miR-23b/27b/24 was found to be elevated in the metastatic variants within these progression series, as well as within lung metastasis samples relative to matched primary human breast cancer tissues. Furthermore, ectopic expression of all three miRNAs within the lowly metastatic 4TO7 mouse breast cancer cell line enhanced lung metastasis. Microarray expression analysis for targets of the miRNAs further uncovered prosaposin (PSAP) as a direct target of miR-24 and miR-27b.

**EXPERIMENTAL PROCEDURES**

**Cell Lines and Cell Culture—**HeLa, 67NR, 168FARN, 4TO7, 66cl4, 4T1, MDA-MB-231 parental and sublines, as well as H29 cells, a packaging cell line used for retrovirus production, were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) containing 10% fetal bovine serum, supplemented with 1 mm 1-glutamine and penicillin/streptomycin (Invitrogen). MCF10A, MCF10AT, MCFCA1h, and MCFCA1a cells were maintained in 1:1 DMEM:Hams F12 medium (Invitrogen) containing 5% horse serum, supplemented with 20 ng/ml EGF, 0.5 mg/ml hydrocortizone, 10 mg ml−1insulin, 1% penicillin/streptomycin and 50 ng/ml chola toxin. miR-23b/27b/24 was amplified from mouse genomic DNA (miR-23b/27b/24, TGTCTGTATGGCCACACAGG (forward primer) and ACGTACGCAATAGCTGCTAG (reverse primer)) using the Phusion High-fidelity DNA Polymerase kit (New England Biolabs) and cloned into the pMSCV-puro vector.

**Quantitative Real-time PCR—**Duplicate arrays were performed for each sample and analyzed with an Agilent G2565BA scanner and Agilent Feature Extraction software (version 9.5). The Cy5/Cy3 ratios were calculated by median signal and normalized by the array median. Probes with >2.5-fold changes were identified as potential direct targets of miR-23/27/24.

**RNA Isolation and Microarray—**RNA for qRT-PCR and microarray was isolated from cultured cells using a miRVana total RNA isolation kit (Ambion) according to the manufacturer’s instructions. For RNA isolation from tumor lesions, the lesions were macroscopically dissected and pulverized using a liquid nitrogen cooled mortar and pestle, followed by RNA isolation with the miRVana kit. For microarrays, samples were analyzed with the Agilent Whole Mouse Genome 4×44k arrays. RNA samples were labeled with Cy5 using the Agilent low RNA input linear amplification kit and were hybridized with the Cy3-labeled human reference RNA (Stratagene). Duplicate arrays were performed for each sample and analyzed with an Agilent G2565BA scanner and Agilent Feature Extraction software (version 9.5). The Cy5/Cy3 ratios were calculated by median signal and normalized by the array median. Probe with >2.5-fold changes were identified as potential direct targets of miR-23/27/24. The miR-23b/27b/24 Cluster Promotes Metastasis
The miR-23b/27b/24 Cluster Promotes Metastasis

GTGGAC-3' (reverse); mouse Otx2, 5'-TATCTAAGCAACCGCCTTACG-3' (forward) and 5'-AAGTCCCATACCCCGAAGTGTC-3' (reverse); mouse Ptk1, 5'-AAGAGACCAATCTCCCTAGC-3' (forward) and 5'-CTCATCACAAGGAAAT-3' (reverse); mouse Pgs, 5'-CTCTGTCCTGTGGAC-3' (forward) and 5'-AGGGAGGATTTCTGCTTGG-3' (reverse); mouse Rnf144, 5'-AGGCTGTTGTAACAGGGATTTG-3' (forward) and 5'-TTGTTGAC-3' (reverse);

Transwell Migration Assay—105 4T07 control or miRNA-overexpressing cells were seeded into the upper chamber of an 8-μm pore transwell migration insert (BD Biosciences) containing serum-free media. Serum-containing DMEM was used as an attractant in the bottom chamber, and cells were allowed to migrate for 12 h. At the conclusion of the experiment, the inserts were removed, and trypsinized cells were counted from the bottom chamber, providing a quantitative value for migrated cells across the membrane. For invasion assays, 1 mg/ml Matrigel (BD Biosciences) was polymerized in the top chamber prior to the addition of cells, which were allowed to invade for 20 h before quantification.

Tumor Xenografts and Bioluminescence Analysis—All procedures involving mice and experimental protocols were approved by Institutional Animal Care and Use Committee of Princeton University. For experimental lung metastasis studies, 105 tumor cells were injected into the lateral tail vein of female BALB/c mice. For orthotopic injections, 106 cells were injected into the mammary gland as described previously (27). Development of primary tumors was analyzed every 4 days, with final measurements performed at end point. Lungs collected from tail vein-injected mice were washed briefly in PBS, followed by overnight fixation in Bouin’s fixative (Sigma) and were stored in 70% ethanol. Lungs from orthotopic injections were minced and digested with 300 units/ml type 1A collagenase (Sigma, C2674) and 100 units/ml hyaluronase (Sigma, H3506) for 60 min at 37 °C. Dissociated cells were passed through a 70-μm strainer and plated into 15-cm plates. 60 μl 2-thioguanine was used to select for 4T07 tumor cells, which were grown for 2 weeks, followed by staining with crystal violet for 30 min for quantification.

Luciferase Reporter Assay—Wild-type and mutant 3'-UTRs were PCR-amplified from human genomic DNA. The 3'-UTRs were cloned into the pMIR-REPORT vector (Ambion) downstream of firefly luciferase. Mutations in miRNA target sites were generated using the QuikChange multisite-directed mutagenesis kit (Stratagene). 5 x 104 HeLa cells were plated in 24-well plates 24 h prior to transfection. 200 ng of reporter plasmid was co-transfected with the Renilla luciferase control plasmid and 10 pm pre-miRNA precursor or precursor control (Ambion) using Lipofectamine 2000 (Invitrogen). Cells were lysed 24 h after transfection and assayed for luciferase activity using the Glomax 96 Luminometer (Promega). Primer sequences for cloning or mutagenesis were: human RAI14, 5'-GGATTCTTTTTGGCAGGACACTTT-3' (forward) and 5'-ATAAATAACGCAATCCCTGACACAA-3' (reverse); human HSS3T2, 5'-GTCTCAGGAGAGCCTATT-3' (forward) and 5'-TTAAGGAGCACGAGAGCCATATT-3' (reverse); human MYH2, 5'-CCCGATGCTGTTGGAATGAC-3' (forward) and 5'-CTTGCTGAAAGAATTCCTGGG-3' (reverse); human OTX2, 5'-CTCTGTAAGAGCTTATTTTTGTTG-3' (forward) and 5'-GACTTCTAGAGCAGCTACG-3' (reverse); human PFTK1, 5'-CCTGAATCGGTTCTCTTGC-3' (forward) and 5'-TGCTATGGTCTATGTTGAGC-3' (reverse); human PSAP, 5'-TTTCCGACGCTGAAATGGTCACCTAC-3' (forward) and 5'-GGCTGTTCTCCTGGCAACCGGAGG-3' (reverse); human RNF144, 5'-TCAAGGCTCCCATATCAAGAGTGG-3' (forward) and 5'-GGAGAGAGCAGACTAATAAGCACAA-3' (reverse); human SACS, 5'-AGGAGAGCAGACTAATAAGCACAA-3' (forward) and 5'-GGAGAGAGCAGACTAATAAGCACAA-3' (reverse); human PSAP-miR-24-1, 5'-AGGCCGGTGAGTAAGCTGAGGGAAGAGA-3' (forward) and 5'-CTCCCTCAGCACCTCCACCGGCTT-3' (reverse); and human PSAP-miR-24-2, 5'-GAGCATTTGTCACGTTCTTGGTTGAGG-3' (forward) and 5'-GACAGGAAGAGGAGAGA-3' (reverse); human PSAP-miR-25-3'-UTRs

RESULTS

miR-23b/27b/24 Expression Correlates with Breast Cancer Lung Metastasis—Previous reports have implicated the miR-23ab/27ab/24 miRNAs as key mediators of metastasis, although there exists uncertainty as to the precise role of the miRNAs during breast cancer metastasis. These clusters are thought to originate from a highly conserved duplication event; miR-23a and -23b and miR-27a and -27b contain minute differences within the mature miRNA sequences, although the seed sequences of the related miRNAs are conserved across clusters, resulting in two highly conserved clusters (Fig. 1A). To examine expression of the miRNAs within metastasis, we utilized matched primary tumor and lung metastasis samples isolated from microdissected tumor samples from breast cancer patients. qRT-PCR analysis of these samples revealed a consistent up-regulation of all miRNAs in the metastatic tissues (Fig. 1B).

To better examine the function these miRNAs during tumor progression, three breast cancer isogenic cell line series were selected that model the progression of breast cancer with increasing metastatic ability: the mouse 4T1 cell line series and the human MCF10A series and MDA-MB-231 series. The 4T1 series, consisting of 67NR, 168FARN, 4TO7, 66cl4, and 4T1...
cells, are a syngenic model derived from a spontaneously arising BALB/cByJ tumor (28). This series displays varied metastatic potential upon orthotopic injection into the mammary gland of mice, with 4T1 and 66cl4 cells producing spontaneous lung metastases, 4T07 forming micrometastases in the lungs, and 67NR and 168FARN forming primary tumors but lacking metastases (28–30). The MCF10A series includes the immortalized, but otherwise normal and non-tumorigenic MCF10A mammary epithelial cell line, as well as in vivo selected derivatives of H-RAS-transformed parental cells with varying metastatic potentials (31). These include the relatively benign MCF10AT cells, which do not typically progress into carcinomas, as well as the low-grade, poorly metastatic carcinoma line MCF10CA1h and the metastatic MCF10CA1a cells. The MDA-MB-231 cell line consists of a weakly metastatic parental line, as well as clonally selected, single cell-derived progenies (SCPs) that feature varying metastatic propensity and organotropism (32, 33). Specifically, although SCP4 and SCP6 cells are essentially non-metastatic, the SCP28, 4173, and 4175 lines are capable of forming overt lung metastases (33).

miR-23a/27a/24 and miR-23b/27b/24 expression levels were examined in these cells by qRT-PCR. Expression of miR-23a, miR-27a, and miR-24 showed a correlation with metastatic potential within the 4T1 (Fig. 1C), MCF10A (Fig. 1D), and MDA-MB-231 progression series (Fig. 1E). miRNA expression of all three members of the miR-23b/27b/24 cluster showed an overall similar but slightly stronger association with metastatic potential (Fig. 1C–E). Given the similarity of these two clusters, we chose to focus on functional analysis of the role of the miR-23b/27b/24 cluster.

The mouse miRNAs were stably overexpressed in the weakly metastatic 4T07 cells using the pMSCV retroviral vector, as verified by qPCR (Fig. 2A). Expression of all three miRNAs in the miR-23b/27b/24 cluster were elevated by ~6–8 fold relative to vector transduced cells, at a level similar to the endogenous miRNA expression found in 4T1 cells (Fig. 1C). Importantly, the overexpression was specific, with no significant changes observed in miR-23a and miR-27a within these cells. Overexpression of miR-23b/27b/24 had no effect on morphology or proliferation within the 4T07 cells (Fig. 2, B and C). Interestingly, miRNA overexpressing cells reduced transwell migration and decreased Matrigel invasion (Fig. 2D), consistent with previous reports of decreased migration upon ectopic expression of miR-23b in prostate cancer cell lines (19).

The miR-23b/27b/24 Cluster Promotes Lung Metastasis—To investigate the influence of the miR-23b/27b/24 cluster miRNAs on metastatic colonization in the lungs, mice were inoculated with vector control or miRNA-overexpressing 4T07 cells via the lateral tail vein and subsequently monitored for the incidence of lung metastasis. Lungs were collected 2 weeks post-injection, and overt lesions were counted. This quantification revealed that miR-23b/27b/24 expression significantly increased the number of lung lesions relative to control (p = 0.0289, Fig. 2, E and F). Interestingly, qRT-PCR analysis revealed that miR-23b/27b/24 levels were modestly elevated in isolated lung lesions beyond that of the in vitro population prior to injection, suggesting that the metastasis process may have selected for clones with elevated expression (Fig. 2G).

To examine the influence of miR-23b/27b/24 on the early steps of metastatic progression, 4T07 cells were inoculated orthotopically into the mammary fat pad of BALB/c mice. Primary tumor growth was comparable between both parental and miR-23b/27b/24-overexpressing 4T07 cells (Fig. 2, H and I), both of which spontaneously disseminated to the lungs but failed to develop into overt lung metastases. Instead, the micrometastatic burden was estimated by culturing tumor colonies from dissociated lungs; quantification of crystal violet-stained colonies revealed a trend toward increased metastasis from mice injected with the miR-23b/27b/24-overexpressing cells, although this did not reach significance (Fig. 2, J and K). Together, these in vivo results indicate that the miR-23b/27b/24 cluster promotes lung metastasis with most of the influence exerted on the step of colonization.
The miR-23b/27b/24 Cluster Promotes Metastasis

Genomic Identification of miR-23b/27b/24 Target Genes—To elucidate the molecular mechanism of miR-23b/27b/24 in enhancing lung metastasis, we employed a combined approach, utilizing microarray analysis and the TargetScan computational target prediction algorithm (34). The microarray analysis detected 24,705 unique genes, revealing 402 genes with >2.5-fold decreased expression in the miRNA-overexpressing cells. To identify potential direct targets of miR-23b/27b/24, the subset of down-regulated genes was analyzed for putative miRNA-binding sites. Candidate target genes were then examined for predicted miRNA binding sites using TargetScan, and eight predicted targets were chosen for further analysis (Fig. 3A). qRT-PCR results validated repression of all eight genes after ectopic miRNA expression (Fig. 3B).

To confirm direct targeting by the miRNAs, the 3′-UTRs from the putative target genes were cloned into the pMIR-REPORT luciferase plasmid. Reporter plasmids were co-transfected into HeLa cells along with the miRNAs of interest and a Renilla luciferase plasmid for normalization. Analysis of luciferase expression revealed that only the prosaposin (Psap) reporter expression was suppressed after ectopic miRNA expression (Fig. 3C). PSAP is a secreted protein that has been described previously as both a metastasis promoter and suppressor (35–37). PSAP mRNA contained three predicted binding sites for the miR-23b/27b/24 clusters within the 3′-UTR, including two for miR-24 and one for miR-27 (Fig. 3D). We confirmed direct targeting through mutagenesis of the predicted miRNA binding sites: mutation of the miR-27 binding site and one of the two miR-24 partially rescued luciferase signal, whereas combined mutagenesis of both miR-24 and miR-27 sites fully rescued luciferase signal (Fig. 3E).

PSAP Expression Is Correlated with Lung Metastasis—Examination of PSAP expression in our cell line models revealed that the mRNA and protein expression level of PSAP decreased in the metastatic variants of the 4T1 and MCF10A isogenic progression series (Fig. 4, A–D). In particular, a significant reduction of PSAP protein and mRNA expression was found in the 4T1 and MCFCA1a cell lines, which represent the most metastatic ones and the only ones capable of forming macrometastases in each series. These findings implicate PSAP as a putative metastasis suppressor, and we next sought to examine the effect of PSAP overexpression on metastatic progression. To this end, mouse and human PSAP was ectopically expressed in 4T1 and MDA-MB-231-SCP28 cells, respectively. Ectopic expression was confirmed by qRT-PCR and Western blot analyses (Fig. 5A), and cells were injected via the lateral tail-vein into mice. Analysis of lung lesions revealed that PSAP suppressed metastasis in both 4T1 and SCP28 cells (Fig. 5B). Importantly, when
Psap was ectopically expressed in 4TO7-miR-23b/27b/24 cells, there was a significant decrease in lung lesions, indicating that re-expression of Psap was capable of partially neutralizing the metastasis-promoting effects of the phenotype resulted from the overexpression of the miR-23b/27b/24 cluster (Fig. 5C).

To further examine the clinical significance of PSAP as a metastasis factor, we analyzed the expression levels of PSAP in publically available clinical datasets, as well as the microdissected primary breast cancer or lung metastasis patient samples from before. Analysis of breast cancer patients using the KM-plotter data set (26) revealed a significant correlation between PSAP expression and increased distant metastasis-free survival, particularly in estrogen receptor-negative breast cancer patients (Fig. 5D). In addition, analysis of patient samples revealed that PSAP expression decreased in lung metastasis samples compared with the primary mammary tumors (Fig. 5E). Together, these results indicate that PSAP is a direct target of the miR-23/27/24 clusters and is reduced during metastasis, both in cell lines and clinical samples.

**DISCUSSION**

miRNA regulation has been implicated in various critical aspects of tumor progression, both as clinical biomarkers and functional regulators of metastasis. Previous in vitro and in vivo studies have implicated the miR-23/27/24 family of miRNAs as both positive and negative regulators of the metastatic cascade. For example, expression of miR-23b and miR-27b has been shown to inhibit migration and anchorage-independent growth in prostate cancer cells (19), whereas miR-23a/27a/24 increases migration and metastasis in breast cancer lines (22). In this study, we show that the expression of the miR-23b/27b/24 cluster is elevated in lung metastasis in human breast cancer and that ectopic expression of the miRNAs promotes lung metastasis in the 4TO7 mouse mammary cell line. Therefore, the miR-23b/27b/24 is likely to have a metastasis-promoting role in lung metastasis of breast cancer.

It is curious that ectopic expression of the miRNAs was capable of increasing the metastatic potential upon intravenous inoculation while possessing much weaker effects on spontaneous metastasis. It is possible that this effect can be attributed in part to limitations within the assay; both 4TO7 vector and miRNA overexpression cells develop visible lesions upon lateral tail vein injection but were unable to develop into overt metastasis in orthotopic experiments. In addition, it is possible that...
The miR-23b/27b/24 Cluster Promotes Metastasis

FIGURE 5. PSAP is a metastasis suppressor and a poor prognosis factor in breast cancer. A, qRT-PCR (upper panel) and Western blot analysis of the expression levels of PSAP in 4T1 or SCP28 cells after transfection of the expression plasmid or vector (Vec). Data represent average ± S.D. B, lung lesion quantification and representative images of lungs from mice injected with vector or PSAP-overexpressing cells from A (p values by Student’s t test). Data represent average ± S.D. C, lung lesion quantification and representative images of lungs from mice injected with indicated SCP28 cells. D, Kaplan-Meier curves showing the distant metastasis free survival of patients with high or low expression of PSAP in breast tumors. p values were computed by a log rank test. E, box plots showing PSAP expression levels in 10 primary and metastasis (Met) samples as quantified by qRT-PCR analysis. p values computed by Student’s t test. Data represent mean ± S.E. normalized to GAPDH expression. ER, estrogen receptor; HR, hazard ratio.

the observed defect in migration and invasion could offset any increase of metastatic colonization abilities conferred by the miRNAs. Future studies will be necessary to further elucidate the influence of the miRNAs on the stepwise progression of breast cancer lung metastasis.

Multiple targets have been identified for members of the miR-23b/27b/24 cluster, including SPRY, ANXA2, ARHGGEF6, CFL2, LIMK2, PIK3R3, PLAU, VEGFC, PTPN9, and PTPRF (21–24). We have additionally uncovered the direct targeting of PSAP by miR-24 and miR-27b. PSAP, a highly conserved precursor for saposins A, B, C, and D, has been identified previously as a functional regulator of metastatic progression (36, 37). Our results show that PSAP mRNA and protein expression correlated with reduced metastatic potential and that ectopic PSAP expression is capable of inhibiting metastasis. Previous studies found that PSAP was down-regulated in metastatic variants of the PC3 prostate cancer and MDA-MB-231 breast cancer cells (36). Finally, PSAP has been shown to increase thrombospondin 1 expression in PC3 cells, and PSAP or a short PSAP-mimetic peptide (DWLPLK) inhibited prostate cancer lung metastasis (38). Future studies will be required to further analyze the functional mechanism of PSAP in suppressing metastatic colonization in the lungs.

Enhanced migration and invasion were canonically believed to increase the metastatic potential of tumor cells, although recent reports have identified highly metastatic cells with decreased migratory capacity (39). Indeed, this is observed within the 4T1 series, in which the most highly metastatic 4T1 cells are actually less migratory (7, 29). Thus, it is not possible to predict metastatic potential through migratory capacity alone. In our current study, overexpression of miR-23b/27b/24 inhibits invasion and migration, while dramatically increasing metastatic colonization in the lungs. This observation is similar to what we previously reported about the miR-200 family miRNAs (7). miRNAs have been shown to influence the expression of hundreds of downstream genes, so it is perhaps not surprising that ectopic expression of three miRNAs might simultaneously influencing separate aspects of the metastatic cascade. The dichotomous functions of these miRNAs in early and late steps of the metastatic cascade may complicate their utilization as therapeutic targets. One possible approach to sidestep this complication is to use the direct target of miR-23b/27b/24, PSAP, or its peptide mimetics, as therapeutic agents against metastasis. Future studies should assess whether PSAP or its functional peptide mimetics may have a therapeutic influence on metastatic progression. The combination of clinical correlation and direct functional inhibition in preclinical mouse models strongly suggests that PSAP is functioning as a metastasis suppressor. Future studies will be required to assess the utility of PSAP as a therapeutic strategy, both as a diagnostic marker for disease progression and as a direct pharmaceutical target.

Acknowledgments—We thank M. Korpal and Y. Wei for expert technical advice and support and members of the Kang laboratory for insightful discussions and technical suggestions. Additionally, we thank F. Miller for the 4T1 cell line series.

REFERENCES
1. Bartel, D. P. (2009) MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233
2. Harquail, J., Benzina, S., and Robichaud, G. A. (2012) MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 11, 269–280
3. Iorio, M. V., and Croce, C. M. (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4, 143–159
4. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., Downing, J. R., Jacks, T., Horvitz, H. R., and Golub, T. R. (2005) MicroRNA expression profiles classify human cancers. Nature 435, 834–838
5. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F.,
The miR-23b/27b/24 Cluster Promotes Metastasis

Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negriani, M., Harris, C. C., and Croce, C. M. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103, 2257–2261

6. Ma, L., Teruya-Feldstein, J., and Weinberg, R. A. (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682–688

7. Korpal, M., Ell, B. J., Buffa, F. M., Ibrahim, T., Blanco, M. A., Celiá-Terrassa, T., Mercatali, L., Khan, Z., Goodarzi, H., Hua, Y., Wei, Y., Hu, G., Garcia, B. A., Ragoussis, J., Amadori, D., Harris, A. L., and Kang, Y. (2011) Direct targeting of Sec23a by miR-20b-65b influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 17, 1101–1108

8. Satzger, I., Mattern, A., Kuettler, U., Weinspach, D., Voelker, B., Kapp, A., and Gutzmer, R. (2010) MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 126, 2553–2562

9. Farazi, T. A., Hoell, J. I., Morozov, P., and Tuschl, T. (2013) MicroRNAs in cancer. Adv. Exp. Med. Biol. 774, 1–20

10. Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., Gerald, W. L., and Massagué, J. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147–152

11. Riaz, M., van Jaarsveld, M. T., Hollestelle, A., Prager-van der Smissen, T., Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., Gerald, W. L., and Massagué, J. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147–152

12. Dew, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., Furth, E. E., Lee, W. M., Enders, G. H., Mendell, J. T., and Thomas, K. (2006) A tumour suppressor panel of microRNA clusters. Nat. Cell Biol. 8, 1427–1437

13. He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Ishteiwy, R. A., Ward, T. M., Dykxhoorn, D. M., and Burnstein, K. L. (2013) miR-23b/27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One 8, e60687

14. Tang, W., Zhu, J., Su, S., Wu, W., Liu, Q., Su, F., and Yu, F. (2012) MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One 7, e51702

15. Gryffty, B., Länzcyzk, A., and Szallász, Z. (2012) Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 19, 197–208

16. Chakrabarti, R., Wang, I., Andres Blanco, M., Wei, Y., Lukacsián, M., Romano, R. A., Smalley, K., Liu, S., Yang, Q., Ibrahim, T., Mercatali, L., Amadori, D., Haffty, B. G., Sinha, S., and Kang, Y. (2012) ELF-2 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 14, 1212–1222

17. Aslakson, C. J., and Miller, F. R. (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405

18. Lou, Y., Proebrozhesnenska, O., auf dem Keller, U., Sutcliffe, M., Barclay, L., McDonald, P. C., Roskelley, C., Overall, C. M., and Dedhar, S. (2008) Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Dev. Dyn. 237, 2755–2768

19. Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzkson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., and Weinberg, R. A. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939

20. Tang, B., Yu, M., Booker, T., Santner, S. J., Miller, F. R., Anver, M. R., and Wakefield, L. M. (2003) TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest. 112, 1116–1124

21. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Oshen, A. B., Gerald, W. L., and Massagué, J. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436, 518–524

22. Minn, A. J., Kang, Y., Yergan, I., Gupta, G. P., Giri, D. D., Dubrovin, M., Ponomarev, V., Gerald, W. L., Blasberg, R., and Massagué, J. (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44–55

23. Grimson, F., Aram, K. F., Johnstone, W. K., Garrett-Engele, P., Lim, L. P., and Bartel, D. P. (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91–105

24. Campana, W. M., O'Brien, J. S., Hiraïwa, M., and Patton, S. (1999) Secretion of prosaposin, a multifunctional protein, by breast cancer cells. Biochim. Biophys. Acta 1427, 392–400

25. Kang, S. Y., Halvorsen, O. J., Gravdal, K., Bhattacharya, N., Lee, J. M., Liu, N. W., Johnston, B. T., Johnston, A. B., Haukaas, S. A., Aamodt, K., Yoo, S., Akslen, L. A., and Watinck, R. S. (2009) Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc. Natl. Acad. Sci. U.S.A. 106, 12115–12120

26. Hu, S., Delorme, N., Liu, Z., Liu, T., Velasco-Gonzalez, C., Garai, J., Pullikuth, A., and Koochekpour, S. (2010) Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Mol. Cancer 9, 30

27. Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., Ryu, S., Joshi, N., Bielenberg, D. L., Lee, S. B., Haukaas, S. A., Gravdal, K., Halvorsen, O. J., Akslen, L. A., Watnick, R. S., and Mittal, V. (2013) Bone marrow-derived Gr1 + cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589

28. Xue, B., Krishnamurthy, K., Allred, D. C., and Muthuswamy, S. K. (2013) Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat. Cell Biol. 15, 189–200